Zentek Ltd. (ZTEK)
USD 0.98
(-4.85%)
USD 0.98
(-4.85%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -11.08 Million CAD | 19.72% |
| 2022 | -13.75 Million CAD | -19.98% |
| 2021 | -11.34 Million CAD | -194.02% |
| 2020 | -4 Million CAD | -146.98% |
| 2019 | -1.56 Million CAD | 36.58% |
| 2018 | -2.46 Million CAD | -50.77% |
| 2017 | -1.63 Million CAD | 42.4% |
| 2016 | -2.83 Million CAD | 32.31% |
| 2015 | -4.19 Million CAD | -37.72% |
| 2014 | -3.04 Million CAD | 13.15% |
| 2013 | -3.5 Million CAD | -30.04% |
| 2012 | -2.69 Million CAD | -58.93% |
| 2011 | -1.69 Million CAD | -10.13% |
| 2010 | -1.53 Million CAD | -902.43% |
| 2009 | -153.53 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -2.41 Million CAD | -4.56% |
| 2023 Q1 | -4.83 Million CAD | -88.16% |
| 2023 FY | - CAD | 19.72% |
| 2023 Q4 | -2.26 Million CAD | 12.82% |
| 2023 Q3 | -2.59 Million CAD | 15.6% |
| 2023 Q2 | -3.07 Million CAD | 36.45% |
| 2022 Q3 | -3.06 Million CAD | 2.27% |
| 2022 Q4 | -2.57 Million CAD | 16.05% |
| 2022 FY | - CAD | -19.98% |
| 2022 Q1 | -4.83 Million CAD | -7.28% |
| 2022 Q2 | -3.13 Million CAD | 35.22% |
| 2021 Q3 | -1.79 Million CAD | 37.46% |
| 2021 Q4 | -4.51 Million CAD | -151.11% |
| 2021 Q2 | -2.87 Million CAD | -59.7% |
| 2021 Q1 | -1.79 Million CAD | -56.82% |
| 2021 FY | - CAD | -194.02% |
| 2020 Q1 | -381.81 Thousand CAD | 42.71% |
| 2020 FY | - CAD | -146.98% |
| 2020 Q2 | -443.32 Thousand CAD | -16.11% |
| 2020 Q3 | -1.88 Million CAD | -325.4% |
| 2020 Q4 | -1.14 Million CAD | 39.18% |
| 2019 Q4 | -666.5 Thousand CAD | -351.22% |
| 2019 Q3 | -147.71 Thousand CAD | 59.79% |
| 2019 Q1 | -380.56 Thousand CAD | 37.55% |
| 2019 Q2 | -367.32 Thousand CAD | 3.48% |
| 2019 FY | - CAD | 36.58% |
| 2018 Q2 | -1.01 Million CAD | -294.63% |
| 2018 Q3 | -582.08 Thousand CAD | 42.63% |
| 2018 Q4 | -609.42 Thousand CAD | -4.7% |
| 2018 FY | - CAD | -50.77% |
| 2018 Q1 | -257.08 Thousand CAD | 45.43% |
| 2017 Q3 | -320.23 Thousand CAD | -6.47% |
| 2017 FY | - CAD | 42.4% |
| 2017 Q4 | -471.11 Thousand CAD | -47.11% |
| 2017 Q2 | -300.77 Thousand CAD | 44.47% |
| 2017 Q1 | -541.63 Thousand CAD | 16.3% |
| 2016 Q2 | -1.02 Million CAD | -159.59% |
| 2016 Q3 | -773.34 Thousand CAD | 24.35% |
| 2016 Q1 | -393.77 Thousand CAD | 44.7% |
| 2016 Q4 | -647.09 Thousand CAD | 16.32% |
| 2016 FY | - CAD | 32.31% |
| 2015 Q3 | -832.01 Thousand CAD | 37.77% |
| 2015 Q4 | -712.1 Thousand CAD | 14.41% |
| 2015 Q1 | -1.3 Million CAD | -120.72% |
| 2015 Q2 | -1.33 Million CAD | -2.13% |
| 2015 FY | - CAD | -37.72% |
| 2014 Q2 | -1.05 Million CAD | -60.78% |
| 2014 FY | - CAD | 13.15% |
| 2014 Q3 | -745.18 Thousand CAD | 29.08% |
| 2014 Q4 | -593.17 Thousand CAD | 20.4% |
| 2014 Q1 | -653.56 Thousand CAD | 1.4% |
| 2013 FY | - CAD | -30.04% |
| 2013 Q1 | -848.64 Thousand CAD | 41.39% |
| 2013 Q2 | -896.35 Thousand CAD | -5.62% |
| 2013 Q3 | -1.09 Million CAD | -22.21% |
| 2013 Q4 | -662.87 Thousand CAD | 39.49% |
| 2012 Q1 | -398.8 Thousand CAD | -25.39% |
| 2012 Q2 | -292.91 Thousand CAD | 26.55% |
| 2012 Q3 | -554.2 Thousand CAD | -89.2% |
| 2012 Q4 | -1.44 Million CAD | -161.29% |
| 2012 FY | - CAD | -58.93% |
| 2011 Q1 | -496.39 Thousand CAD | -7.86% |
| 2011 Q2 | -513.7 Thousand CAD | -3.49% |
| 2011 Q3 | -366.87 Thousand CAD | 28.58% |
| 2011 Q4 | -318.04 Thousand CAD | 13.31% |
| 2011 FY | - CAD | -10.13% |
| 2010 FY | - CAD | -902.43% |
| 2010 Q3 | -655.45 Thousand CAD | -164.57% |
| 2010 Q1 | -175.65 Thousand CAD | -14.54% |
| 2010 Q2 | -247.74 Thousand CAD | -41.04% |
| 2010 Q4 | -460.22 Thousand CAD | 29.79% |
| 2009 Q4 | -153.35 Thousand CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -45.63 Million USD | 75.713% |
| AngioDynamics, Inc. | -14.29 Million USD | 22.455% |
| AtriCure, Inc. | -8.1 Million USD | -36.671% |
| Avinger, Inc. | -16.34 Million USD | 32.199% |
| Azenta, Inc. | 55.15 Million USD | 120.095% |
| BioLife Solutions, Inc. | -45.23 Million USD | 75.501% |
| The Cooper Companies, Inc. | 882.8 Million USD | 101.255% |
| Daxor Corporation | 329.74 Thousand USD | 3461.038% |
| Ekso Bionics Holdings, Inc. | -13.19 Million USD | 16.028% |
| Femasys Inc. | -13.16 Million USD | 15.845% |
| GlucoTrack, Inc. | -7.09 Million USD | -56.292% |
| Harvard Bioscience, Inc. | 9.49 Million USD | 216.746% |
| Hologic, Inc. | 1.29 Billion USD | 100.855% |
| ICU Medical, Inc. | 307.69 Million USD | 103.602% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 100.463% |
| KORU Medical Systems, Inc. | -9.39 Million USD | -17.906% |
| LeMaitre Vascular, Inc. | 48.99 Million USD | 122.622% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -68.555% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -68.555% |
| Masimo Corporation | 236.7 Million USD | 104.682% |
| Microbot Medical Inc. | -10.63 Million USD | -4.219% |
| Meihua International Medical Technologies Co., Ltd. | 15.77 Million USD | 170.275% |
| Merit Medical Systems, Inc. | 231.44 Million USD | 104.789% |
| Nephros, Inc. | -1.37 Million USD | -703.676% |
| NovoCure Limited | -175.86 Million USD | 93.698% |
| NEXGEL, Inc. | -2.73 Million USD | -305.959% |
| NEXGEL, Inc. | -2.73 Million USD | -305.959% |
| Singular Genomics Systems, Inc. | -86.49 Million USD | 87.187% |
| OraSure Technologies, Inc. | 76.15 Million USD | 114.552% |
| Pro-Dex, Inc. | 8.33 Million USD | 232.998% |
| Pulse Biosciences, Inc. | -42.36 Million USD | 73.841% |
| Predictive Oncology Inc. | -13.18 Million USD | 15.926% |
| Precision Optics Corporation, Inc. | -2.51 Million USD | -341.198% |
| QuidelOrtho Corporation | 545.6 Million USD | 102.031% |
| Repligen Corporation | 124.29 Million USD | 108.917% |
| Sanara MedTech Inc. | -289.09 Thousand USD | -3733.553% |
| STAAR Surgical Company | 33.22 Million USD | 133.36% |
| Sharps Technology, Inc. | -8.98 Million USD | -23.41% |
| Utah Medical Products, Inc. | 24.8 Million USD | 144.679% |
| DENTSPLY SIRONA Inc. | 232 Million USD | 104.777% |
| Jin Medical International Ltd. | 3.44 Million USD | 421.901% |